ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Systemic sclerosis"

  • Abstract Number: 0704 • ACR Convergence 2025

    Human Pharmacokinetics of Inhaled Liposomal Iloprost Support a Dosing Regimen for Treating Systemic Sclerosis- Related Digital Ulcer

    Pei Kan, Ko-Chieh Chen and Shin-Shin Chuang, Pharmosa Biopharm Inc, Taipei, Taiwan (Republic of China)

    Background/Purpose: Iloprost is recommended and widely used in Europe for treating systemic sclerosis (SSc)-related Raynaud Phenomena (RP) and Digital Ulcer (DU). EULAR recommendation suggests continuous…
  • Abstract Number: 0675 • ACR Convergence 2025

    Neutrophil-to-Lymphocyte Ratio as a biomarker for disease onset and a predictor for mortality in Systemic Sclerosis – real-world data from a large healthcare provider in Israel.

    Shiri Keret1, Shlomit Yaari2, gleb Slobodin3 and doron Rimar3, 1Bnai Zion Medical Center, Atlit, Israel, 2Maccabi Healthcare Services, HaMered 27, Tel Aviv, 68125, Israel., Tel Aviv, Israel, 3Bnai Zion Medical Center Faculty of Medicine, Technion Israel institute of technology, Haifa, Israel

    Background/Purpose: Elevated neutrophil-to-lymphocyte ratio (NLR) in systemic sclerosis (SSc) has been demonstrated to predict worsening skin and lung involvement, and a cutoff of 2.95 was…
  • Abstract Number: 0810 • ACR Convergence 2025

    Spatial Transcriptomic-based Phenotyping of the Fibroblast Niches in Systemic Sclerosis-associated Primary Heart Involvement

    Alexandru Micu1, Alexandru-Emil Matei2, Yi-Nan Li3, Ann-Christin Pecher4, Tim Filla5, Jörg Henes6, Markus Eckstein7, Karin Klingel8, Jörg Distler9 and Andrea-Hermina Györfi10, 1Department of Rheumatology, University Hospital Düsseldorf, Medical Faculty of Heinrich-Heine University. Hiller Research Center, University Hospital Düsseldorf, Medical Faculty of Heinrich-Heine University, Düsseldorf, Germany, 2Department of Rheumatology, University Hospital Düsseldorf, Medical Faculty of Heinrich-Heine University. Hiller Research Center, University Hospital Düsseldorf, Medical Faculty of Heinrich-Heine University. Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, and Fraunhofer Cluster of Excellence for Immune Mediated Diseases CIMD, Frankfurt am Main, Germany, Düsseldorf, Germany, 3University Hospital of Düsseldorf, Düsseldorf, Germany, 4Department of Internal Medicine II, Hematology, Oncology, Clinical Immunology, and Rheumatology, University Hospital Tübingen, Tübingen, Germany, 5Department of Rheumatology, University Hospital Düsseldorf, Medical Faculty of Heinrich-Heine University. Hiller Research Center, University Hospital Düsseldorf, Medical Faculty of Heinrich-Heine University., Düsseldorf, Germany, 6Department of Internal Medicine II, Hematology, Oncology, Clinical Immunology, and Rheumatology, University Hospital Tübingen, Tuebingen, Germany, 7Institute of Pathology and Comprehensive Cancer Center EMN, Friedrich-Alexander- Universität (FAU) Erlangen-Nürnberg and Uniklinikum Erlangen, Erlangen, Germany, 8Cardiopathology, Institute for Pathology, Eberhard-Karls-Universität Tübingen, Tübingen, Germany, 9University Hospital Duesseldorf and HHU, Duesseldorf, Germany, 10Department of Rheumatology, University Hospital Düsseldorf, Medical Faculty of Heinrich Heine University., Düsseldorf, Germany

    Background/Purpose: Systemic sclerosis (SSc)-associated primary heart involvement (SSc-pHI) is one of the leading causes of mortality in SSc, yet its underlying cellular and molecular pathomechanisms…
  • Abstract Number: 2652 • ACR Convergence 2025

    Anti-mitochondrial antibodies in systemic sclerosis target enteric neurons and are associated with GI dysmotility

    Zsuzsanna McMahan1, Srinivas Puttapaka2, Livia Casciola-Rosen3, Timothy Kaniecki3, Laura Gutierrez3, Su Hong MIng2, Philippa Seika2 and Subhash Kulkarni4, 1UT Health Houston, Houston, TX, 2BIDMC/Harvard, Boston, MA, 3Johns Hopkins University, Baltimore, MD, 4BIDMC, Boston, MA

    Background/Purpose: Most patients with systemic sclerosis (SSc) experience gastrointestinal (GI) dysmotility. The enteric nervous system (ENS) regulates GI motility, and its dysfunction causes dysmotility. A…
  • Abstract Number: 2483 • ACR Convergence 2025

    Is There a Seasonal Variation in Raynaud’s Phenomenon Severity in Patients with Systemic Sclerosis?

    Gulsen Ozen1, Lan Yu2, Maureen Lauffoon2, John Pauling3 and Robyn Domsic2, 1University of Iowa Carver College of Medicine, Coralville, IA, 2University of Pittsburgh, Pittsburgh, PA, 3North Bristol NHS Trust, Bristol, United Kingdom

    Background/Purpose: Raynaud’s phenomenon (RP) is the most common manifestation of systemic sclerosis (SSc) leading to substantial pain and impaired hand function. Establishing treatment efficacy for…
  • Abstract Number: 1871 • ACR Convergence 2025

    Examining the impact of ETV2 on altered endothelial phenotype in systemic sclerosis

    Elio Carmona1, Alyssa Rosek2, Neha Khanna2, Dinesh Khanna3, Amr Sawalha4 and Pei-Suen Tsou3, 1Division of Pediatric Rheumatology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA, Pittsburgh, 2Division of Rheumatology, Department of Internal Medicine, University of Michigan, Ann Arbor, MI, USA, Ann Arbor, 3University of Michigan, Ann Arbor, MI, 4University of Pittsburgh, Pittsburgh, PA

    Background/Purpose: Our prior research demonstrated that epigenetic modifications are central to the pathogenesis of scleroderma (SSc)1. Using ATAC-seq, we found that chromatin accessibility was significantly…
  • Abstract Number: 1582 • ACR Convergence 2025

    Risk factors for incident digital ischemic complications in systemic sclerosis in the Collaborative National Quality and Efficacy Registry (CONQUER)

    Marissa Savoie1, Monica Harding2, John VanBuren2, Shervin Assassi3, Elana Bernstein4, Lorinda Chung5, Luke Evnin6, Tracy Frech7, Jessica Gordon1, Faye Hant8, Laura Hummers9, Dinesh Khanna10, Kimberly Lakin1, Dorota Lebiedz-Odrobina2, Yiming Luo4, Ashima Makol11, Maureen Mayes12, Zsuzsanna McMahan13, Jerry Molitor14, Duncan Moore15, Carrie Richardson16, Nora Sandorfi17, Ami Shah9, Ankoor Shah18, Brian Skaug19, Virginia Steen20, Elizabeth Volkmann21, Carleigh Zahn10 and Flavia Castelino22, 1Hospital for Special Surgery, New York, NY, 2University of Utah, Salt Lake City, UT, 3Division of Rheumatology, UTHealth Houston, Houston, Texas, USA, Houston, TX, 4Columbia University, New York, NY, 5Stanford University, Stanford, CA, 6Scleroderma Research Foundation, Brisbane, CA, 7Vanderbilt University Medical Center, Nashville, TN, 8Medical University of South Carolina, Charleston, SC, 9Johns Hopkins Rheumatology, Baltimore, MD, 10University of Michigan, Ann Arbor, MI, 11Mayo Clinic, Rochester, MN, 12UT Health Houston Division of Rheumatology, Houston, TX, 13UT Health Houston, Houston, TX, 14University of Minnesota, Minneapolis, MN, 15Northwestern Memorial Hospital, Chicago, IL, 16Northwestern University, Chicago, IL, 17University of Pennsylvania, Philadelphia, PA, 18Duke University, Durham, NC, 19UTHealth Houston Division of Rheumatology, Houston, TX, 20Georgetown University School of Medicine, Washington, DC, 21Division of Rheumatology, Department of Medicine, University of California, David Geffen School of Medicine, Los Angeles, CA, USA, Los Angeles, CA, 22Massachusetts General Hospital, Boston, MA

    Background/Purpose: There have not been large US-based studies of digital pitting scars (DPS) and digital ischemic ulcers (DIU) in systemic sclerosis. Utilizing the Collaborative National…
  • Abstract Number: 1553 • ACR Convergence 2025

    Circulating Monocyte Level Is Associated With Pulmonary Vascular Disease and Right Ventricular Dysfunction in Systemic Sclerosis

    Ai Yaku1, Bong Joon Kim2, Hidenori Yaku1, Carrie Richardson2, Michael Cuttica2, Ruben Mylvaganam2, Vera Rigolin2, Matthew Feinstein2 and Sanjiv Shah1, 1Northwestern University, Chicago, IL, 2Northwestern University, Chicago

    Background/Purpose: Pulmonary arterial hypertension associated with systemic sclerosis (SSc-PAH) is a life-threatening condition with obliterative pulmonary vascular remodeling, right ventricular (RV) dysfunction, and poor prognosis.…
  • Abstract Number: 0970 • ACR Convergence 2025

    Genomic instability in systemic sclerosis is promoted by metabolic remodelling via a FOXO1-dependent axis

    Lamia Khan1, Junqin Wang2, Aishwarya Iyer2, Desiree Redmond2, Dylan Hennessey2, Sandra O'Keefe2, Jan Storek3, Charmaine van Eeden2, Robert Gniadecki2 and Mohammed Osman1, 1University of Alberta, Edmonton, AB, Canada, 2Department of Medicine, University of Alberta, Edmonton, AB, Canada, 3University of Calgary, Calgary, AB, Canada

    Background/Purpose: Systemic sclerosis (SSc) is a life-threatening autoimmune disease with limited treatment options, including autologous hematopoietic stem cell transplantation (AHSCT). We recently showed that dermal…
  • Abstract Number: 0702 • ACR Convergence 2025

    Effectiveness of Oral Anticoagulants in Precapillary Pulmonary Hypertension Associated with Systemic Sclerosis: a EUSTAR Cohort Study.

    Nicola Farina1, Silvia Bellando-Randone2, hilde Bjørkekjær3, David Launay4, Patricia E. Carreira5, paolo airò6, Serena Guiducci7, Dilia Giuggioli8, Gabriela Riemekasten9, carmen-Pilar Simeón Aznar10, Christina Bergmann11, Elise Siegert12, Ivan Castellví13, Lesley Ann Saketkoo14, Jeska de Vries-Bouwstra15, Dr. Philipp Klemm16, ulf Müller-Ladner17, Alexandra Balbir- Gurman18, Vanessa Smith19, Florenzo Iannone20, Luca Idolazzi21, Christopher Denton22, edoardo rosato23, Britta Maurer24, Yannick Allanore25, Yoshiya Tanaka26, elisabetta zanatta27, Marie-Elise Truchetet28, Masataka Kuwana29, Mickaël MARTIN30, Alberto Cauli31, Kamal Solanki32, Francesco Del Galdo33, Ana Maria Gheorghiu34, Branimir Anic35, Gábor Kumánovics36, Gonçalo Boleto37, Kristofer Andréasson38, Simona Rednic39, Lorinda Chung40, susana Oliveira41, marius cadar42, Francesco Paolo Cantatore43, Carolina de Souza Müller44, Vivien Hsu45, Yair Levy46, Gianluca Moroncini47, Jörg Henes48, Andra Balanescu49, and Ellen De Langhe50, , Carlomaurizio Montecucco51, Petros Sfikakis52, Michele Iudici53, Stefan Heitmann54, Madelon Vonk55, Anna-Maria Hoffmann-Vold56, Oliver Distler57, Marco Matucci-Cen58, Cosimo Bruni57, 1Department of Experimental and Clinical Medicine, Scleroderma Unit, Division of Rheumatology, University of Florence, Azienda Ospedaliera Universitaria Careggi, Florence, Italy. Unit of Immunology, Rheumatology, Allergy and Rare Diseases, IRCCS San Raffaele Hospital, Milan, Italy, Milan, Italy, 2University of Florence, Florence, Florence, Italy, 3Department of Rheumatology, Hospital of Southern Norway, Kristiansand, Norway, olso, Norway, 4Univ. Lille, Inserm, CHU Lille, Department of Internal Medicine and Clinical Immunology, Reference Center for Rare Autoimmune and Autoinflammatory diseases (CERAINOM), U1286 - INFINITE - Institute for Translational Research in Inflammation, Lille, France. National Reference Center for Pulmonary Arterial Hypertension (Pulmotension), Lille, France, Lille Cedex, France, 5Hospital Universitario 12 de Octubre, Madrid, Spain, 6Rheumatology and Clinical Immunology Unit, ASST Spedali Civili of Brescia, University of Brescia, Brescia, Italy, brescia, Italy, 7Department of Experimental and Clinical Medicine, Scleroderma Unit, Division of Rheumatology, University of Florence, Azienda Ospedaliera Universitaria Careggi, Florence, Italy, Pistoia, Italy, 8Scleroderma Unit, Rheumatology Unit, University Hospital of Modena and Reggio Emilia, Modena, Italy, Modena, Italy, 9University Clinic Schleswit-Holstein (UKSH), Lübeck, Germany, 10Hospital Universitario Vall d'Hebron Passeig, Department of Internal Medicine, Systemic Autoimmune Diseases Unit, Barcelona, Spain, Zaragoza, Spain, 11Department of Medicine 3 - Rheumatology and Immunology, Friedrich-Alexander-Universität (FAU) Erlangen-Nürnberg and Uniklinikum Erlangen, Erlangen, Germany, 12Charité University Hospital, Department of Rheumatology, Berlin, Germany, Berlin, Germany, 13Hospital de la Santa Creu i Sant Pau, Barcelona, Spain, barcelona, Spain, 14University Medical Center - Comprehensive Pulmonary Hypertension Center and ILD Clinic Programs // New Orleans Scleroderma and Sarcoidosis Patient Care & Research Centeris, New Orleans, LA, 15Leiden University Medical Center, Leiden, Netherlands, 16Kerckhoff-Klinik Bad Nauheim, Berlin, Germany, 17JLU Giessen, Campus Kerckhoff, Department of Rheumatology and Clinical Immunology Center, Bad Nauheim, Germany, Bad Nauheim, Germany, 18Rambam Health Care Campus, Rheumatology Institute, Haifa, Israel, israel, Israel, 19Ghent University Hospital, Gent, Belgium, 20Rheumatology DiMePReJ, University of Bari, School of Medicine, Bari, Italy, Bari, Italy, 21Section of Rheumatology, Department of Medicine, University of Verona, Verona, Italy, verona, Italy, 22University College London, UK, London, United Kingdom, 23Sapienza University of Rome, Department of Translational and Precision Medicine Azienda Ospedaliero-Universitaria Policlinico Umberto 1-Centro di riferimento regionale per la sclerosi sistemica, Rome, Italy, rome, Italy, 24Department of Rheumatology & Immunology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland, 25Université Paris Cité, Paris, France, 26University of Occupational and Environmental Health, Japan, Kitakyushu, Japan, 27Padova University Hospital, Rheumatology Unit, Padova, Italy, padova, Italy, 28Bordeaux University Hospital, Bordeaux, France, 29Nippon Medical School Graduate School of Medicine, Tokyo, Japan, 30Poitiers University Hospital, Department of Internal Medicine, Poitiers, France, MIGNALOUX-BEAUVOIR, France, 31Rheumatology Unit, Department of Medicine and Public Health, AOU and University of Cagliari, Cagliari, Italy, 32Waikato Hospital, Hamilton, New Zealand, 33University of Leeds, Leeds, United Kingdom, 34Spitalul Clinic Dr. Ion Cantacuzino, Bucharest, Romania, 35University of Zagreb, School of Medicine, University Hospital Center Zagreb, Division of Clinical Immunology and Rheumatology, Department of Internal Medicine, Zagreb, Croatia, zagreb, Croatia, 36University of Pécs, Department Of Rheumatology And Immunology, Medical Centre, Pecs, Hungary, Pecs, Hungary, 37Local de Saúde Santa Maria, Centro Académico de Medicina de Lisboa, Rheumatology Department, Lisbon, Portugal, Paris, France, 38Skåne University Hospital, Department of Rheumatology, Lund, Sweden, Lund, Sweden, 39University of Medicine and Pharmacy Iuliu Hatieganu Cluj, Clinica Reumatologie, Cluj-Napoca, Romania, Cluj-Napoca, Romania, 40Stanford University, Stanford, CA, 41Fernando Fonseca Hospital, Department of Medicine IV, Systemic Immunomediated Diseases Unit, Amadora, Portugal, amadora, Portugal, 42Sapienza University of Rome, Rheumatology Clinic, Rome, Italy, Rome, Italy, 43University of Foggia, Department of Medical and Surgical Sciences, Rheumatology Unit, Foggia, Italy, foggia, Italy, 44Hospital de Clinicas da Universidade Federal do Parana, Curitiba, Brazil, curitiba, Brazil, 45Rutgers- RWJ Medical School, South Plainfield, NJ, 46Meir Medical Center, Kfar-Saba, Israel, Kefar Sava, Israel, 47Department of Internal Medicine, Marche University Hospital, Clinica Medica, Ancona, Italy, Ancona, Italy, 48Department of Internal Medicine II, Hematology, Oncology, Clinical Immunology, and Rheumatology, University Hospital Tübingen, Tuebingen, Germany, 49UNIVERSITY OF MEDICINE AND PHARMACY CAROL DAVILA, Bucharest, Romania, 50University Hospital Leuven, Laboratory of Tissue Homeostasis and Disease, Department of Development and Regeneration, KU Leuven, Leuven, Belgium, Leuven, Belgium, 51Università di Pavia e IRCCS Fondazione Policlinico S. Matteo, Pavia, Italy, 52NKUA - SCHOOL OF MEDICIN, Athens, Greece, 53Division of Rheumatology, Department of Internal Medicine Specialties, Geneva University Hospitals, Geneva, Switzerland, 54Department of Rheumatology, Marienhospital Stuttgart, Böheimstrasse 37, D-70199 Stuttgart, Germany, 55Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, 56Oslo University Hospital, Oslo, Norway, 57Department of Rheumatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland, 58University San Raffaele Milano, Milano, Italy

    Background/Purpose: Precapillary pulmonary hypertension (PH) in systemic sclerosis (SSc) associates with severe morbidity and mortality. The prothrombotic state observed in idiopathic pulmonary arterial hypertension (PAH)…
  • Abstract Number: 0674 • ACR Convergence 2025

    Quantitative Imaging in Systemic Sclerosis Patients Receiving Sodium Thiosulfate for Calcinosis Cutis

    Ian Odell1, Crystal Cheung1, Megan Wu2, Stephanie Perez3, Agrani Dixit4, Cassandra van Horn3, Muhammad Hamdan5, Baran Gunes6, Sophia Kujawski7, Hyojeong Lee3, Annie Wang3, Denise Esserman8, Michael Zamani9, F. Perry Wilson3, John Onofrey3, Xenophon Papademetris3 and Monique Hinchcliff10, 1Yale University School of Medicine, New Haven, CT, 2Yale University School of Medicine, Greenville, 3Yale University School of Medicine, New Haven, 4Yale School of Medicine, New Haven, CT, 5Yale University School of Medicine, Mansfield, 6Yale University School of Medicine, Pompton Plains, NJ, 7The George Washington University, New Haven, CT, 8Yale University School of Public Health, New Haven, 9Independent Statistician, Washington D.C., 10Yale School of Medicine, Westport, CT

    Background/Purpose: Calcinosis cutis (CC) is a disabling skin condition associated with systemic sclerosis (SSc). Although many CC treatments including sodium thiosulfate (STS) have been proposed,…
  • Abstract Number: 0809 • ACR Convergence 2025

    Human blood vessel organoids as a model of vasculopathy in systemic sclerosis

    Yanhua Xiao1, Xuezhi Hong1, Langxian Zhi1, Yi-Nan Li2, Martin Regensburger3, Franz Marxreiter4, Boris Görg5, Sarah Koziel6, Andrea-Hermina Györfi7, Tim Filla8, Peter-Martin Bruch6, Philipp Tripal9, James Adjaye10, Sascha Dietrich11, Jürgen Winkler4, Jörg Distler12 and Alexandru-Emil Matei13, 1Medical Faculty of Heinrich Heine University, Dusseldorf, Germany, 2University Hospital of Düsseldorf, Düsseldorf, Germany, 3Department of Stem Cell Biology, Friedrich-Alexander-Universität (FAU) Erlangen-Nürnberg, Erlangen, Germany, Erlangen, Germany, 4Department of Molecular Neurology, FAU Erlangen-Nürnberg, Erlangen, Germany, Erlangen, Germany, 5Heinrich-Heine University, Dusseldorf, Germany, 6University Hospital Düsseldorf, Dusseldorf, Germany, 7Department of Rheumatology, University Hospital Düsseldorf, Medical Faculty of Heinrich Heine University., Düsseldorf, Germany, 8Department of Rheumatology, University Hospital Düsseldorf, Medical Faculty of Heinrich-Heine University. Hiller Research Center, University Hospital Düsseldorf, Medical Faculty of Heinrich-Heine University., Düsseldorf, Germany, 9University Hospital Erlangen, FAU Erlangen-Nürnberg, Erlangen, 10Institute for Stem Cell Research and Regenerative Medicine, University Hospital Düsseldorf, Moorenstrasse 5, D-40225 Duesseldorf, Germany, Dusseldorf, Germany, 11Heinrich Heine University Duesseldorf, University Hospital Duesseldorf, Duesseldorf, Germany, 12University Hospital Duesseldorf and HHU, Duesseldorf, Germany, 13Department of Rheumatology, University Hospital Düsseldorf, Medical Faculty of Heinrich-Heine University. Hiller Research Center, University Hospital Düsseldorf, Medical Faculty of Heinrich-Heine University. Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, and Fraunhofer Cluster of Excellence for Immune Mediated Diseases CIMD, Frankfurt am Main, Germany, Düsseldorf, Germany

    Background/Purpose: While several pathogenic processes involved in vasculopathy in systemic sclerosis (SSc) have been described1-3, the mechanisms that underlie the SSc microvasculopathy remain incompletely understood.…
  • Abstract Number: 2555 • ACR Convergence 2025

    Ergonomic Modifications: Findings From the Making it WorkTM Systemic Sclerosis Program

    Janet Poole1, Mary Thelander1 and Kristine Carandang2, 1University of New Mexico, Albuquerque, NM, 2Young Patients' Autoimmune Research & Empowerment Alliance, San Diego, CA

    Background/Purpose: Work disability in people with systemic sclerosis (SS) increases substantially from diagnosis to three years after disease onset.  Ergonomic modifications help people with physical,…
  • Abstract Number: 2482 • ACR Convergence 2025

    Characterizing Gastrointestinal Involvement in Systemic Sclerosis: Insights from the National Systemic sclerosis Progression INvestiGation (SPRING) Registry of the Italian Society of Rheumatology

    Francesco Bonomi1, Cosimo Bruni2, Silvia Laura Bosello3, Fabio Cacciapaglia4, Corrado Campochiaro5, Roberto Caporali6, Veronica Codullo7, Maria Antonietta D'Agostino8, Lorenzo Dagna9, Rossella De Angelis10, Giacomo de Luca11, Dilia Giuggioli12, Serena Guiducci13, Florenzo Iannone14, Francesca Ingegnoli15, Carlomaurizio Montecucco7, Valeria Riccieri16, Clodoveo Ferri17, Marco Matucci-Cerinic18 and Silvia Bellando Randone19, 1University Hospital Careggi, Florence, Florence, Toscana, Italy, 2University of Zurich, Zurich, Switzerland, 3Division of Rheumatology and Clinical Immunology - Catholic University of the Sacred Heart, Rome, Italy, Rome, Italy, 4Rheumatology Unit DiMePRe-J, University and AOU Policlinico of Bari & Department of Medicine LUM "G. De Gegnnaro" University, Casamassima (Bari) - Italy, Bari, Italy, 5IRCCS San Raffaele Hospital. Vita-Salute San Raffaele University, Milan, Milan, Italy, 6University of Milan and ASST Gaetano Pini-CTO, Milano, Italy, 7Policlinico San Matteo, Pavia, Pavia, Italy, 8Catholic University of the Sacred Heart, Rome, Rome, Italy, 9Ospedale San Raffaele, Milano, Italy, 10Polytechnic University of Marche, Ancona, Ancona, Italy, 11Vita-Salute San Raffaele University. Unit of Immunology, Rheumatology, Allergy and Rare Diseases, IRCCS San Raffaele Hospital, Milan, Italy, 12Rheumatology Unit, Department of Medical and Surgical Sciences for Children and Adults, University Hospital of Modena and Reggio Emilia School of Medicine, Italy., Modena, Emilia-Romagna, Italy, 13Division of Rheumatology, Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy, Florence, Italy, 14Rheumatology DiMePReJ, University of Bari, School of Medicine, Bari, Italy, Bari, Italy, 15Clinica Reumatologica, Dipartimento di Reumatologia e Scienze Mediche, ASST Gaetano Pini-CTO, Dipartimento di Scienze Cliniche e di Comunità, Dipartimento di Eccellenza 2023-2027, Università degli Studi di Milano, Milan, Italy, Milan, Italy, 16Sapienza University of Rome, Rheumatology Clinic, Rome, Italy, Roma, Italy, 17University of Modena and Reggio Emilia, Modena, Modena, Italy, 18University San Raffaele Milano, Milano, Milan, Italy, 19University of Florence, Florence, Italy

    Background/Purpose: Gastrointestinal (GI) involvement affects over 80% of patients with systemic sclerosis (SSc), contributing significantly to morbidity and representing the third leading cause of disease-related…
  • Abstract Number: 1868 • ACR Convergence 2025

    Global Downregulation of Fli1 in Mice Induces Cardiac Dysfunction via Enhanced β-fatty acid Oxidation and Collagen Deposition

    Knowledge Mudhibadhi Moyo1, Fatima-Ezzahrae El Adili2, Maria Trojanowska1 and Andreea Bujor1, 1Boston University, Boston, MA, 2Boston University School of Medicine, Revere, MA

    Background/Purpose: Primary cardiac involvement is a common complication of Systemic sclerosis (SSc), characterized by fibrosis and diastolic dysfunction, presumably due to microvascular dysfunction and repeated…
  • « Previous Page
  • 1
  • …
  • 5
  • 6
  • 7
  • 8
  • 9
  • …
  • 56
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology